PIK3CA is an inclusion criterion in 37 clinical trials for breast carcinoma, of which 29 are open and 8 are closed. Of the trials that contain PIK3CA status and breast carcinoma as inclusion criteria, 11 are phase 1 (6 open), 7 are phase 1/phase 2 (6 open), 15 are phase 2 (14 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (2 open) [4].

Alpelisib and fulvestrant have evidence of efficacy in patients with PIK3CA mutation in breast carcinoma [4].

Ivosidenib has evidence of efficacy in patients with PIK3CA mutation in breast invasive lobular carcinoma [4].

PIK3CA is an inclusion criterion in 37 clinical trials for malignant solid tumor, of which 26 are open and 11 are closed. Of the trials that contain PIK3CA status and malignant solid tumor as inclusion criteria, 18 are phase 1 (10 open), 6 are phase 1/phase 2 (4 open), 12 are phase 2 (11 open), and 1 is phase 4 (1 open) [4].

PIK3CA is an inclusion criterion in 10 clinical trials for non-small cell lung carcinoma, of which 5 are open and 5 are closed. Of the trials that contain PIK3CA status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open), 4 are phase 1/phase 2 (2 open), and 4 are phase 2 (3 open) [4].

PIK3CA is an inclusion criterion in 8 clinical trials for colorectal carcinoma, of which 4 are open and 4 are closed. Of the trials that contain PIK3CA status and colorectal carcinoma as inclusion criteria, 4 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 5 clinical trials for endometrial carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PIK3CA status and endometrial carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [4].

PIK3CA is an inclusion criterion in 5 clinical trials for melanoma, of which 3 are open and 2 are closed. Of the trials that contain PIK3CA status and melanoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 2 are closed. Of the trials that contain PIK3CA status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 3 clinical trials for cancer, of which 1 is open and 2 are closed. Of the trials that contain PIK3CA status and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 2 are phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 3 clinical trials for colon adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3CA status and colon adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 3 (2 open) [4].

PIK3CA is an inclusion criterion in 3 clinical trials for gastric adenocarcinoma, of which 1 is open and 2 are closed. Of the trials that contain PIK3CA status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 2 are phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3CA status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

PIK3CA is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PIK3CA status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PIK3CA status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3CA status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [4].

PIK3CA is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 1 is closed. Of the trials that contain PIK3CA status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3CA status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 2 clinical trials for breast adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and breast adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [4].

PIK3CA is an inclusion criterion in 2 clinical trials for chondrosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3CA status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

PIK3CA is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].

PIK3CA is an inclusion criterion in 2 clinical trials for undifferentiated pleomorphic sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CA status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for angiosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and angiosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for colon carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and colon carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for extraskeletal osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and extraskeletal osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and follicular lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CA status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and invasive breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CA status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and myxofibrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for myxoid liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and myxoid liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for pleomorphic liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and pleomorphic liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for pleomorphic rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and pleomorphic rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for rectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and rectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and rectal carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CA status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PIK3CA is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].